Alto Neuroscience (NYSE:ANRO) Hits New 52-Week High After Analyst Upgrade

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price hit a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $50.00 to $55.00. HC Wainwright currently has a buy rating on the stock. Alto Neuroscience traded as high as $34.35 and last traded at $33.70, with a volume of 863655 shares changing hands. The stock had previously closed at $32.14.

ANRO has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday. Bank of America initiated coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective on the stock. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Finally, Robert W. Baird decreased their price objective on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $37.25.

Institutional Trading of Alto Neuroscience

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at $67,000. AQR Capital Management LLC acquired a new stake in Alto Neuroscience during the 1st quarter worth $52,000. Marshall Wace LLP lifted its position in Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after acquiring an additional 84,417 shares during the last quarter. Jane Street Group LLC purchased a new stake in Alto Neuroscience in the second quarter valued at $240,000. Finally, Bridgeway Capital Management LLC lifted its position in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the last quarter.

Alto Neuroscience Stock Up 1.8%

The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -14.13 and a beta of 1.06. The firm’s 50 day simple moving average is $26.54 and its 200-day simple moving average is $23.04.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08. As a group, sell-side analysts anticipate that Alto Neuroscience, Inc. will post -2.71 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.